Skip to main content
Erschienen in: Clinical Rheumatology 9/2013

01.09.2013 | Original Article

Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody

verfasst von: A. Srivastava, G. K. Rao, P. E. Segal, M. Shah, D. Geetha

Erschienen in: Clinical Rheumatology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

A subset of patients with crescentic glomerulonephritis (CGN) is characterized serologically by the presence of antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody (anti-GBM) called “double positive” disease. The clinical significance of the occurrence of both antibodies is not clear. This study aims to describe the clinical and histologic characteristics and outcomes of CGN in a US cohort of double positive (DP) patients and compare them to patients with anti-GBM disease only or ANCA only (ANCA-associated vasculitis (AAV)). Renal biopsies with a diagnosis of CGN with either pauci-immune or linear immunofluorescence were selected and classified as AAV, anti-GBM disease, or DP based on serologic testing at the time of biopsy. Data on demographics, clinical presentation, treatment, and outcome were obtained by chart review. Six patients with anti-GBM disease, 9 with DP disease, and 18 AAV patients matched for year of diagnosis with DP were identified. Extrarenal disease manifestations were more prominent in the DP patients. The DP patients had severe renal dysfunction at presentation with eight of nine patients requiring dialysis at presentation. Renal biopsy findings of DP patients were similar to anti-GBM disease with majority of glomeruli showing cellular crescents. Eighty-nine percent of patients were treated with immunosuppressive therapy and 78 % with plasmapheresis. At 1 year, all nine DP patients reached end-stage renal disease. We conclude that the DP patients share extrarenal manifestations similar to AAV patients while the renal manifestations resemble anti-GBM patients clinically and histologically. The renal prognosis of DP patients remains poor despite treatment.
Literatur
1.
Zurück zum Zitat Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44PubMedCrossRef Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44PubMedCrossRef
2.
Zurück zum Zitat Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042PubMedCrossRef Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042PubMedCrossRef
3.
Zurück zum Zitat O'Donoghue DJ, Short CD, Brenchley PE, Lawler W, Ballardie FW (1989) Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 32:251–255PubMed O'Donoghue DJ, Short CD, Brenchley PE, Lawler W, Ballardie FW (1989) Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 32:251–255PubMed
4.
Zurück zum Zitat Jia XY, Cui Z, Yang R, Hu SY, Zhao MH (2012) Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury. Clin J Am Soc Nephrol 7:926–933PubMedCrossRef Jia XY, Cui Z, Yang R, Hu SY, Zhao MH (2012) Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury. Clin J Am Soc Nephrol 7:926–933PubMedCrossRef
5.
Zurück zum Zitat Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (2010) Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363:343–354PubMedCrossRef Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (2010) Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363:343–354PubMedCrossRef
6.
Zurück zum Zitat Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, Wang HY (2007) Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 18:1338–1343PubMedCrossRef Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, Wang HY (2007) Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 18:1338–1343PubMedCrossRef
7.
Zurück zum Zitat Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, Yuan CM (2011) Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22:1946–1952PubMedCrossRef Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, Yuan CM (2011) Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22:1946–1952PubMedCrossRef
8.
Zurück zum Zitat Jayne DR, Marshall PD, Jones SJ, Lockwood CM (1990) Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965–970PubMedCrossRef Jayne DR, Marshall PD, Jones SJ, Lockwood CM (1990) Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965–970PubMedCrossRef
9.
Zurück zum Zitat Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C (1997) Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 8:376–385PubMed Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C (1997) Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 8:376–385PubMed
10.
Zurück zum Zitat Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66:1535–1540PubMedCrossRef Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66:1535–1540PubMedCrossRef
11.
Zurück zum Zitat Bosch X, Mirapeix E, Font J, Borrellas X, Rodriguez R, Lopez-Soto A, Ingelmo M, Revert L (1991) Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36:107–113PubMed Bosch X, Mirapeix E, Font J, Borrellas X, Rodriguez R, Lopez-Soto A, Ingelmo M, Revert L (1991) Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36:107–113PubMed
12.
Zurück zum Zitat Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262PubMedCrossRef Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262PubMedCrossRef
13.
Zurück zum Zitat Zhao J, Yang R, Cui Z, Chen M, Zhao MH, Wang HY (2007) Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract 107:c56–c62PubMedCrossRef Zhao J, Yang R, Cui Z, Chen M, Zhao MH, Wang HY (2007) Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract 107:c56–c62PubMedCrossRef
14.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMedCrossRef Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMedCrossRef
15.
Zurück zum Zitat Cui Z, Zhao MH, Xin G, Wang HY (2005) Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract 99:c49–c55PubMedCrossRef Cui Z, Zhao MH, Xin G, Wang HY (2005) Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract 99:c49–c55PubMedCrossRef
16.
Zurück zum Zitat Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59–c68PubMedCrossRef Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59–c68PubMedCrossRef
Metadaten
Titel
Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody
verfasst von
A. Srivastava
G. K. Rao
P. E. Segal
M. Shah
D. Geetha
Publikationsdatum
01.09.2013
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 9/2013
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2268-5

Weitere Artikel der Ausgabe 9/2013

Clinical Rheumatology 9/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.